HTB South

Transmission

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

Update on baseline STIs in UK oral PrEP study (PROUD)

HIV reinfection has limited impact on disease progression

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

HIV self testing to become legal in the UK from April 2014

Use of ART at baseline by “treatment na├»ve” patients in HPTN-052

Partner-dependent immune differences may protect against HIV infection

Bangkok Tenofovir Study: US CDC recommends oral PrEP for injection drug users

Tenofovir DF ring protects macaques from vaginal exposure

VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals

Further studies on how male circumcision may reduce HIV transmission

Minimal risk of sexual HIV transmission for heterosexual couples when the HIV positive partner has an undetectable viral load

UK group describe risk of HIV transmission for people on effective ART as “extremely low”

HPTN-052: clinical advantages from earlier treatment

Online video interviews between researchers and activists

PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection

Risk of HIV reinfection may be similar to risk of initial HIV infection

Early data for rilpivirine long acting formulation supports further investigation for PrEP

WHO guidelines for testing, counselling and treatment in serodifferent couples: ART at CD4 >350 to reduce transmission

NICE guideline on fertility treatment proposes alternatives to sperm washing

International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy

Orange Farm circumcision results dispel concerns about risk compensation

Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred prior to viral suppression

Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study

Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP

Treatment reduces infections by over 90%: a theme that is here to stay

Male circumcision: new data supporting protective mechanism

A caution for male circumcision programmes: high complication rates highlighted outside a trial setting

PRO 2000 microbicide gel does not pan out

Results from HSV-2 acyclovir studies

Intermittent tenofovir/FTC PrEP offers monkeys some protection

Tenofovir/FTC gel protects female monkeys from SHIV

Common estimate of heterosexual HIV transmission risk sometimes far too low

Implications of transmission with undetectable HIV viral load: lower limit for HIV transmission excluded from model

HIV RNA is detectable in semen in 5% patients with undetectable blood plasma viral attending fertility clinic

Tenofovir gel as a rectal microbicide: evidence for protection and priming of T-cell responses in the SIV challenge model

Genetic protection against malaria may increase susceptibility to HIV infection in people of African decent